Clinical efficacy of belimumab in patients with systemic lupus erythematosus and headache. A report of two cases. Issue 1 (11th August 2021)

• Record Type: Journal Article
• Authors: Kodera, Takao; Tsutsumi, Tomomi; Oka, Yumiko; Takeda, Tomoki; Shirota, Yuko; Kameoka, Junichi
• Is Part Of: Modern rheumatology case reports. Volume 6:Issue 1(2022)
• Page Start: 25
• Page End: 28
• Publication Date: 2021-08-11
• Subjects: Systemic lupus erythematosus -- neuropsychiatric systemic lupus erythematosus -- lupus headache -- belimumab -- NPSLE; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/mrcr/rxab003
• Languages: English
• ISSNs: 2472-5625

Abstract

ABSTRACT: Intractable headache, one of the manifestations of neuropsychiatric systemic lupus erythematosus (SLE), is difficult to diagnose and decide on an appropriate treatment. In addition to conventional therapy based on the type of headache, the treatment should be conducted considering the disease activity of SLE rather than the headache. We report two patients with intractable headache who were successfully treated using belimumab therapy. The headaches in both patients were relieved after 2 weeks of belimumab administration. The neutralisation of B lymphocyte stimulator and reduced production of cytokines from B lymphocytes might contribute to the early effects. The potential benefits of using belimumab as an additional immunosuppressant for treating intractable headache complicated with SLE have been discussed.